


Stabilis



Meropenem



蝠 刀蜷

Acus	縹 √ M, 縹輔 Λ 縹ウ縹ケ, 縹械 ㊦ 縹シ縹キ縹「
Amplium	縹悶 Λ 縹ク縹ヲ, 縹。縹ユ縹キ縹ウ
Anfletec	縹「縹ヲ縹シ縹ウ縹 √ Φ
Biomerem	縹呐口縹コ縹イ縹ウ
Klopenem	縹「縹ヲ縹シ縹ウ縹 √ Φ
Mectinex	縹 √ M
Meprim	縹イ縹ッ縹「縹峨 N, 縹 √ M
Merinfec	縹「縹、縹ケ縹ウ縹ウ縹
Merobac	縹イ縹ッ縹「縹峨 N, 縹ウ縹ユ縹ウ縹薙い, 縹壹 N 縹シ
Meromax	縹 √ M, 縹悶 Λ 縹ク縹ヲ
Meropen	縹「縹、縹ケ縹ウ縹ウ縹 縹「縹、縹ヲ縹ウ縹ウ縹 縹「縹ウ縹夜ヲ夜聞蝗ス騾」騾ヲ, 縹、縹ヨ縹エ縹ケ, 縹イ縹ッ縹「縹峨 N, 縹イ縹ク縹励ヨ, 縹エ縹ウ縹ウ縹, 縹ヨ縹エ縹キ縹「, 縹ッ縹ユ縹「縹 √ い, 縹ウ縹ユ縹ウ縹薙い, 縹ヲ縹ヲ縹ケ縹「縹ウ縹薙い, 縹ケ縹、縹ケ, 縹ケ縹ヲ縹ア縹シ縹 Φ, 縹ケ縹壹ウ縹ウ, 縹ケ縹ユ縹呐ル縹「, 縹ソ縹、, 縹 √ M, 縹 Φ 縹械 縹ッ, 縹医 N 縹ウ, 縹峨ウ縹 縹弱 N 縹ヲ縹ア縹シ, 縹上 Φ 縹ヤ縹エ縹シ, 縹輔ウ縹ウ縹ウ縹ウ縹 縹悶 Λ 縹ク縹ヲ, 縹呐 N 縹ヨ縹シ, 縹壹 N 縹シ, 縹昂 N 縹医ギ縹ヲ, 縹昂縹ウ縹ウ縹 縹ヲ縹ッ縹サ縹ウ縹悶 N 縹-, 縹ヲ縹シ縹械ル縹「
Meropen	
Merozan	縹医 N 縹ウ
Merrem	縹「縹。縹エ縹ヲ, 縹「縹シ縹ケ縹医 Λ 縹エ縹「, 縹、縹ソ縹エ縹「, 縹ヲ縹翫ム, 縹九 H 縹シ縹ク縹シ縹ウ縹 縹輔 Λ 縹ウ縹ケ, 縹。縹ユ縹キ縹ウ
Optinem	縹エ縹シ縹ケ縹医 M 縹「



		1 mg/ml	2-8ツ-C		2			4922
		2,5 mg/ml	1ツ-C-26ツ-C		24			10
		2,5 & 50 mg/ml	4ツ-C		48			10
		40 mg/ml	25ツ-C		12			3112
		50 mg/ml	21-26ツ-C		8			10
		50 mg/ml	23-27ツ-C		7			4403
		10 mg/ml	2-8ツ-C		48			1639
		10 mg/ml	24ツ-C		6			1639
		2,5 mg/ml	21-26ツ-C		24			10
		2,5 & 50 mg/ml	4ツ-C		48			10
		5 mg/ml	2-8ツ-C		96			1639
		5 mg/ml	24ツ-C		24			1639
		50 mg/ml	21-26ツ-C		8			10
		2,5 & 50 mg/ml	21-26ツ-C		3			10
		2,5 & 50 mg/ml	4ツ-C		24			10
		1 mg/ml	2-8ツ-C		2			4922
		1 mg/ml	21-26ツ-C		24			10
		1 mg/ml	4ツ-C		48			10
		20 mg/ml	21-26ツ-C		10			10
		20 mg/ml	4ツ-C		48			10
		1 mg/ml	-20ツ-C		33			1275
		1 mg/ml	21-26ツ-C		24			10
		1 mg/ml	23ツ-C		22			1275
		1 mg/ml	4ツ-C		10			1275
		1 & 20 mg/ml	4ツ-C		48			10
		10 mg/ml	25ツ-C		12			4290
		10 & 20 mg/ml	5ツ-C		5			1942
		14,2 mg/ml	22ツ-C		7			4122
		14,2 mg/ml	33ツ-C		5			4122
		20 mg/ml	21-26ツ-C		10			10

PVC		22 mg/ml	-20℃-C		11			1275
PVC		22 mg/ml	23℃-C		17			1275
PVC		22 mg/ml	4℃-C		4			1275
PVC		4 mg/ml	5℃-C		7			1942
PVC		1 mg/ml	-20℃-C		1			1275
PVC		1 mg/ml	21-26℃-C		4			10
PVC		1 mg/ml	23℃-C		4			1275
PVC		1 mg/ml	4℃-C		18			10
PVC		1 mg/ml	4℃-C		1			1275
PVC		20 mg/ml	21-26℃-C		3			10
PVC		20 mg/ml	4℃-C		16			10
PVC		22 mg/ml	-20℃-C		7			1275
PVC		22 mg/ml	23℃-C		8			1275
PVC		22 mg/ml	4℃-C		2			1275
PVC		0,25 mg/ml	6℃-C		7			3922
POF		10 mg/ml	22-28℃-C		4			2793
POF		4 mg/ml	22-28℃-C		4			2793
		1 mg/ml	2-8℃-C		2			4922
		10 mg/ml	25℃-C		12			4147
		10 mg/ml	25℃-C		8			4326
		20 mg/ml	22℃-C		17			4592
		20 mg/ml	25℃-C		12			4147
		20 mg/ml	25℃-C		8			4326
		40 mg/ml	25℃-C		8			4147
		40 mg/ml	25℃-C		4			4326
		41,7 mg/ml	20-25℃-C		8			4634
		41,7 mg/ml	20-25℃-C		4			4634
		1 mg/ml	2-8℃-C		2			4922
		10 mg/ml	2-8℃-C		96			1639
		10 mg/ml	24℃-C		6			1639
		10 & 20 mg/ml	5℃-C		5			1942
		4 mg/ml	5℃-C		7			1942
		5 mg/ml	2-8℃-C		96			1639

		5 mg/ml	24ツ-C		24			1639
		64 mg/ml	25ツ-C		5			2042
		64 mg/ml	37ツ-C		1			2042
		20 & 30 mg/ml	5ツ-C		24			1454
		5 mg/ml	20ツ-C		8			3837
		5 mg/ml	23-27ツ-C		12			4403
		5 mg/ml	32-37ツ-C		4			3837
		5 mg/ml	4ツ-C		24			4403
		5 mg/ml	23-27ツ-C		4			4403



豺ヲ蝮域函縛ヲ蝮牙ヲ壽 7

							
		0,5 mg/ml	37℃-C		Heparin sodium : 0,5 UI/ml	10 	4180
		0,5 mg/ml	4℃-C		Heparin sodium : 0,5 UI/ml	168 	4180
		0,5 mg/ml	37℃-C		Heparin sodium : 0,5 UI/ml	10 	4180
		0,5 mg/ml	4℃-C		Heparin sodium : 0,5 UI/ml	168 	4180
		0,5 mg/ml	37℃-C		Heparin sodium : 0,5 UI/ml	10 	4180
		0,5 mg/ml	4℃-C		Heparin sodium : 0,5 UI/ml	168 	4180
		0,5 mg/ml	37℃-C		Heparin sodium : 0,5 UI/ml	10 	4180
		0,5 mg/ml	4℃-C		Heparin sodium : 0,5 UI/ml	168 	4180
		4 mg/ml	25 >> -15℃-C		Tedizolid phosphate : 0.8 mg/ml	8 	4405
		4 mg/ml	2-8℃-C		Tedizolid phosphate : 0.8 mg/ml	6 	4405
		4 mg/ml	25℃-C		Tedizolid phosphate : 0.8 mg/ml	12 	4405



蝮牙ヲ壽 7 縛ヲ蝮ア髻ヲ縛啖k 蝮 蝮

				4403
				5066
				3837
				2120
				3112
				4122
				5066
				3112



				
		Meropenem : 20 mg/ml Aciclovir sodium : 5 mg/ml		266
		Meropenem Aciclovir sodium		3595
		Meropenem : 1 & 50 mg/ml Aciclovir sodium : 5 mg/ml		266
		Meropenem : 50 mg/ml Amikacin sulfate : 250 mg/ml		4319
		Meropenem Amikacin sulfate		3549
		Meropenem : 50 mg/ml Amikacin sulfate : 250 mg/ml		4389
		Meropenem : 1 & 20 mg/ml Aminophylline : 1 mg/ml		266
		Meropenem : 1 & 50 mg/ml Aminophylline : 25 mg/ml		266
		Meropenem : 50 mg/ml Amiodarone hydrochloride : 50 mg/ml		4319
		Meropenem : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Meropenem : 1 & 20 mg/ml Amphotericin B : 0.2 mg/ml		266
		Meropenem : 1 & 50 mg/ml Amphotericin B : 5 mg/ml		266
		Meropenem : 50 mg/ml Amphotericin B liposomale : 2 mg/ml		4319
		Meropenem : 50 mg/ml Ampicillin sodium : 250 mg/ml		4319
		Meropenem : 2.5 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Meropenem : 1 & 50 mg/ml Atenolol : 0.5 mg/ml		266
		Meropenem : 1 & 20 mg/ml Atropine sulfate : 0.04 mg/ml		266
		Meropenem : 1 & 50 mg/ml Atropine sulfate : 0.4 mg/ml		266
		Meropenem : 50 mg/ml Atropine sulfate : 0.4 mg/ml		4319
		Meropenem : 50 mg/ml Azithromycine : 100 mg/ml		4319
		Meropenem : 50 mg/ml Aztreonam : 100 mg/ml		4319
		Meropenem : 50 mg/ml Aztreonam : 100 mg/ml		4389
		Meropenem : 50 mg/ml Benztropine mesylate : 1 mg/ml		4319
		Meropenem : 8.3 mg/ml Blinatumomab : 0.125 & 0.375 մգ/ml		3976

		Meropenem : 50 mg/ml Bretylum tosilate : 50 mg/ml		4319
		Meropenem : 50 mg/ml Bupivacaine hydrochloride : 5 mg/ml		4319
		Meropenem : 50 mg/ml Caffeine : 10 mg/ml		3964
		Meropenem : 50 mg/ml Caffeine : 10 mg/ml		4837
		Meropenem : 50 mg/ml Caffeine citrate : 20 mg/ml		4319
		Meropenem : 50 mg/ml Caffeine citrate : 20 mg/ml		4837
		Meropenem : 50 mg/ml Calcium chloride : 100 mg/ml		4319
		Meropenem : 1 mg/ml Calcium gluconate : 4 mg/ml		266
		Meropenem : 50 mg/ml Calcium gluconate : 100 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Calcium gluconate : 1 mg/ml		266
		Meropenem : 50 mg/ml Calcium gluconate : 4 mg/ml		266
		Meropenem : 50 mg/ml Caspofungin acetate : 0.5 mg/ml		4319
		Meropenem : 10 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Meropenem : 2,5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Meropenem : 50 mg/ml Cefazolin sodium : 100 mg/ml		4319
		Meropenem : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Meropenem : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Meropenem : 50 mg/ml Cefotaxime sodium : 100 mg/ml		4319
		Meropenem : 50 mg/ml Cefoxitin sodium : 100 mg/ml		4319
		Meropenem : 50 mg/ml Ceftazidime : 100 mg/ml		4389
		Meropenem : 50 mg/ml Ceftazidime : 100 mg/ml		4319
		Meropenem : 10 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Meropenem : 10 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Meropenem : 50 mg/ml Ceftriaxone disodium : 100 mg/ml		4319
		Meropenem : 50 mg/ml Cefuroxime sodium : 100 mg/ml		4319
		Meropenem : 50 mg/ml Ciclosporin : 5 mg/ml		4319

		Meropenem : 10 mg/ml Ciclosporin : 1 mg/ml		2335
		Meropenem : 1 & 50 mg/ml Cimetidine hydrochloride : 150 mg/ml		266
		Meropenem : 1 & 20 mg/ml Cimetidine hydrochloride : 3 mg/ml		266
		Meropenem : 50 mg/ml Ciprofloxacin lactate : 2 mg/ml		4319
		Meropenem : 20 mg/ml Ciprofloxacin lactate : 2 mg/ml		3475
		Meropenem : 50 mg/ml Clindamycin phosphate : 150 mg/ml		4319
		Meropenem : 50 mg/ml Cloxacillin sodium : 250 mg/ml		4319
		Meropenem : 50 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Meropenem : 50 mg/ml Co-trimoxazole : 80/16 mg/ml		4319
		Meropenem : 50 mg/ml Colistin mesilate sodium : 75 mg/ml		4319
		Meropenem : 10 mg/ml Colistin mesilate sodium : 1.5 mg/ml		3997
		Meropenem Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Meropenem : 1 & 50 mg/ml Dexamethasone sodium phosphate : 10 mg/ml		266
		Meropenem : 50 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		266
		Meropenem : 50 mg/ml Dexmedetomidine : 100 µg/ml		4319
		Meropenem : 50 mg/ml Diazepam : 5 mg/ml		4319
		Meropenem : 1 & 50 mg/ml Diazepam : 5 mg/ml		266
		Meropenem : 1 & 50 mg/ml Digoxin : 250 µg/ml		266
		Meropenem : 50 mg/ml Digoxin : 250 µg/ml		4319
		Meropenem : 50 mg/ml Dimenhydrinate : 10 mg/ml		4319
		Meropenem : 1 & 50 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		266
		Meropenem : 1 & 20 mg/ml Diphenhydramine hydrochloride : 0.08 mg/ml		266
		Meropenem : 50 mg/ml Dipyridamol : 5 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Dobutamine hydrochloride : 1 mg/ml		266
		Meropenem : 50 mg/ml Dobutamine hydrochloride : 12.5 mg/ml		4319

		Meropenem : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Meropenem : 1 & 20 mg/ml Dopamine hydrochloride : 0.8 mg/ml		266
		Meropenem : 50 mg/ml Dopamine hydrochloride : 32 mg/ml		4319
		Meropenem : 50 mg/ml Ertapenem : 100 mg/ml		4319
		Meropenem : 50 mg/ml Furosemide : 10 mg/ml		4319
		Meropenem : 20 mg/ml		1415
		Meropenem : 20 mg/ml Eravacycline : 0,6 mg/ml		4434
		Meropenem : 20 mg/ml Fosfomycin : 30 mg/ml		4055
		Meropenem		4572
		Meropenem : 50 mg/ml Erythromycin lactobionate : 50 mg/ml		4319
		Meropenem : 50 mg/ml Esmolol hydrochloride : 10 mg/ml		4319
		Meropenem : 50 mg/ml Fentanyl citrate : 50 ʹg/ml		4319
		Meropenem : 50 mg/ml Fluconazole : 2 mg/ml		4319
		Meropenem : 50 mg/ml Foscarnet sodium : 24 mg/ml		4319
		Meropenem : 50 mg/ml		3948
		Meropenem : 1 mg/ml Doxycycline hyclate : 0.2 & 1 mg/ml		266
		Meropenem : 50 mg/ml Epinephrine hydrochloride : 1000 ʹg/ml		4319
		Meropenem		3922
		Meropenem : 20 & 50 mg/ml Doxycycline hyclate : 0,2 & 1 mg/ml		266
		Meropenem : 1 >> 50 mg/ml Enalaprilate : 0.05 mg/ml		266
		Meropenem Erythromycin lactobionate		3674
		Meropenem : 20 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
		Meropenem : 1 >> 50 mg/ml Fluconazole : 2 mg/ml		266
		Meropenem : 20 mg/ml Fosfomycin : 30 mg/ml		4055
		Meropenem : 1 & 20 mg/ml Furosemide : 1 mg/ml		266
		Meropenem : 1 & 50 mg/ml Furosemide : 10 mg/ml		266
		Meropenem : 50 mg/ml		3948

		Meropenem : 10 mg/ml Gentamicin sulfate : 30 mg/ml		2335
		Meropenem : 5 mg/ml		4440
		Meropenem : 50 mg/ml	RL	4603
		Meropenem : 50 mg/ml Gentamicin sulfate : 40 mg/ml		4319
		Meropenem : 50 mg/ml Granisetron hydrochloride : 1 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Heparin sodium : 20 UI/ml		266
		Meropenem		5066
		Meropenem		5066
		Meropenem : 1 & 50 mg/ml Gentamicin sulfate : 4 mg/ml		266
		Meropenem : 1 & 20 mg/ml Gentamicin sulfate : 0.8 mg/ml		266
		Meropenem : 0.5 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Meropenem : 0.5 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Meropenem : 0.5 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Meropenem : 1 & 50 mg/ml Heparin sodium : 1 UI/ml		266
		Meropenem : 0.5 mg/ml Heparin sodium : 0.5 UI/ml		4180
		Meropenem : 50 mg/ml Heparin sodium : 1000 UI/ml		4319
		Meropenem : 50 mg/ml Hydralazine hydrochloride : 20 mg/ml		4319
		Meropenem : 20 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
		Meropenem : 50 mg/ml Hydrocortisone sodium succinate : 125 mg/ml		4319
		Meropenem : 50 mg/ml Hydromorphone hydrochloride : 10 mg/ml		4319
		Meropenem : 50 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		4319
		Meropenem : 50 mg/ml Imipenem - cilastatin sodium : 50 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Insulin : 1 UI/ml		266
		Meropenem : 50 mg/ml Insulin : 100 UI/ml		4319
		Meropenem : 1 & 50 mg/ml Insulin : 0.2 UI/ml		266
		Meropenem : 20 mg/ml Insulin aspart : 1 UI/ml		1508
		Meropenem : 20 mg/ml Insulin aspart : 1 UI/ml		1508

		Meropenem : 10 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Meropenem : 10 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Meropenem : 50 mg/ml Isoprenaline hydrochloride : 0.2 mg/ml		4319
		Meropenem : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Meropenem : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		4319
		Meropenem : 50 mg/ml L-carnitine : 200 mg/ml		4319
		Meropenem : 50 mg/ml Labetalol hydrochloride : 5 mg/ml		4319
		Meropenem : 20 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
		Meropenem : 50 mg/ml Lidocaine hydrochloride : 10 mg/ml		4319
		Meropenem : 50 mg/ml Linezolid : 2 mg/ml		4319
		Meropenem : 2.5 mg/ml Linezolid : 2 mg/ml		1925
		Meropenem : 50 mg/ml Magnesium sulfate : 500 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Magnesium sulfate : 1 mg/ml		266
		Meropenem : 50 mg/ml Mannitol : 250 mg/ml		4319
		Meropenem : 50 mg/ml Methylprednisolone sodium succinate : 62.5 mg/ml		4319
		Meropenem : 1 & 50 mg/ml Metoclopramide hydrochloride : 5 mg/ml		266
		Meropenem : 1 & 20 mg/ml Metoclopramide hydrochloride : 0.1 mg/ml		266
		Meropenem : 50 mg/ml Metoclopramide hydrochloride : 5 mg/ml		4319
		Meropenem : 20 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879
		Meropenem : 50 mg/ml Metoprolol tartrate : 1 mg/ml		4319
		Meropenem : 1 >> 50 mg/ml Metronidazole : 5 mg/ml		266
		Meropenem : 50 mg/ml Metronidazole : 5 mg/ml		4319
		Meropenem : 50 mg/ml Midazolam hydrochloride : 1 mg/ml		4319
		Meropenem : 50 mg/ml Milrinone lactate : 1 mg/ml		4319
		Meropenem : 50 mg/ml Morphine sulfate : 50 mg/ml		4319
		Meropenem : 1 >> 50 mg/ml Morphine sulfate : 1 mg/ml		266

		Meropenem : 50 mg/ml N-acetylcysteine : 200 mg/ml		4319
		Meropenem : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml		4319
		Meropenem : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Meropenem : 50 mg/ml Nitroglycerin : 5 mg/ml		4319
		Meropenem : 50 mg/ml Nitroprusside sodium : 25 mg/ml		4319
		Meropenem : 1 & 50 mg/ml Norepinephrine bitartrate : 1 mg/ml		266
		Meropenem : 1 & 20 mg/ml Norepinephrine bitartrate : 8 mg/ml		266
		Meropenem : 50 mg/ml Norepinephrine bitartrate : 1 mg/ml		4319
		Meropenem : 50 mg/ml Ondansetron hydrochloride : 2 mg/ml		4319
		Meropenem : 1 mg/ml Ondansetron hydrochloride : 1 mg/ml		266
		Meropenem : 20 & 50 mg/ml Ondansetron hydrochloride : 1 mg/ml		266
		Meropenem : 10 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Meropenem : 50 mg/ml Oxytocin : 10 UI/ml		4319
		Meropenem Pantoprazole sodium		2090
		Meropenem : 50 mg/ml Pantoprazole sodium : 4 mg/ml		4319
		Meropenem : 50 mg/ml Paracetamol : 10 mg/ml		4742
		Meropenem : 50 mg/ml Penicillin G sodium : 0.5 MUI/ml		4319
		Meropenem : 50 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Meropenem : 1 & 50 mg/ml Phenobarbital sodium : 0.32 mg/ml		266
		Meropenem : 1 & 20 mg/ml Phenobarbital sodium : 0.2 mg/ml		266
		Meropenem : 50 mg/ml Phenytoin sodium : 50 mg/ml		4319
		Meropenem : 50 mg/ml Piperacillin sodium : 200 mg/ml		4319
		Meropenem : 50 mg/ml Piperacillin sodium / tazobactam : 200 mg/ml		4319
		Meropenem : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Meropenem Posaconazole		4380
		Meropenem : 50 mg/ml Potassium chloride : 2000 mEq/l		4319

		Meropenem : 50 mg/ml Potassium phosphate : 3 mmol/ml		4319
		Meropenem : 50 mg/ml Procainamide hydrochloride : 100 mg/ml		4319
		Meropenem : 50 mg/ml Propranolol hydrochloride : 1 mg/ml		4319
		Meropenem : 1 & 20 mg/ml Ranitidine hydrochloride : 0.1 mg/ml		266
		Meropenem : 50 mg/ml Ranitidine hydrochloride : 25 mg/ml		4319
		Meropenem : 50 mg/ml Rocuronium bromide : 10 mg/ml		4319
		Meropenem : 50 mg/ml Salbutamol sulfate : 1 mg/ml		4319
		Meropenem : 50 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Meropenem : 25 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Meropenem : 50 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Meropenem : 25 mg/ml Sildenafil citrate : 0.06 mg/ml		4845
		Meropenem : 50 mg/ml Sildenafil citrate : 0.06 mg/ml		4845
		Meropenem : 50 mg/ml Sodium bicarbonate : 84 mg/ml		4319
		Meropenem : 50 mg/ml Sodium Phosphate : 3 mmol/ml		4319
		Meropenem : 50 mg/ml Sufentanil citrate : 0.05 mg/ml		4319
		Meropenem : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Meropenem : 4 mg/ml Tedizolid phosphate : 0.8 mg/ml		4405
		Meropenem : 10 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Meropenem : 10 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Meropenem : 10 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Meropenem : 10 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Meropenem Temocilline		4470
		Meropenem : 50 mg/ml Temocilline : 83.33 mg/ml		2231
		Meropenem : 50 mg/ml Thiopental sodium : 25 mg/ml		3767
		Meropenem : 50 mg/ml Tobramycin sulfate : 40 mg/ml		4319
		Meropenem : 50 mg/ml Tobramycin sulfate : 40 mg/ml		4389

	Meropenem : 50 mg/ml Valproic acid : 100 mg/ml		4319
	 Meropenem : 50 mg/ml Vancomycin hydrochloride : 50 mg/ml		4319
	Meropenem : 1 & 20 mg/ml Vancomycin hydrochloride : 1 mg/ml		266
	Meropenem : 1 & 50 mg/ml Vancomycin hydrochloride : 5 mg/ml		266
	Meropenem : 5 mg/ml Vasopressin : 0.2 UI/ml		2017
	Meropenem : 50 mg/ml Voriconazole : 10 mg/ml		4319
	Meropenem : 1 mg/ml Zidovudine : 4 mg/ml		266
	 Meropenem : 20 & 50 mg/ml Zidovudine : 4 mg/ml		266



諡穂ク守ヲ瑚キッ



蠟慕畑譚 鍵

	蠟「蠟	蟹コ迎育黄
10	髪題	Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health-Syst Pharm 1997 ; 54: 412-421.
266	髪題	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
1275	髪題	Walker SE, Varrin S, Yannicelli D, Law S. Stability of meropenem in saline and dextrose solutions and compatibility with potassium chloride. Can J Hosp Pharm 1998 ; 51: 156-168.
1415	髪題	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1454	髪題	Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quiniliani R. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health-Syst Pharm 2000 ; 57: 992-995.
1508	髪題	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1639	髪題	Krř, mer I. Stability of meropenem in elastomeric portable infusion devices. Eur Hosp Pharm 1997 ; 3: 168-171.
1754	髪題	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.

1925	髪題	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1942	髪題	Smith DL, Bauer SM, Nicolau DP. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. Am J Health-Syst Pharm 2004 ; 61: 1682-1685.
1982	髪題	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	髪題	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2042	髪題	Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal β -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2090	髪題	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	髪題	Pelletier E, Forest JM, Hildgen P. Compatibilit� de la k�tatamine injectable lors de l'administration en d�riv� avec d'autres m�dicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2120	髪題	Mendez A.S.L, Dalomo J, Steppe M; Schapoval E.E.S. Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. J Pharm Biomed Anal 2006 ; 41: 1363-1366.
2231	髪題	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	髪題	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	髪題	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Am J Health-Syst Pharm 2008 ; 65, 5: 476-478.
2335	髪題	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2793	髪題	Tomasello C, Leggieri A, Cavalli R, Di Perri G, D'Avolio A. In Vitro Stability Evaluation of Different Pharmaceutical Products Containing Meropenem. Hosp Pharm 2015 ; 50, 4 : 296-303.
3012	髪題	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3112	髪題	Berthoin K, Le Duff, CS , Marchand-Brynaert J, Carryn S, Tulkens PM Stability of meropenem and doripenem solutions for administration by continuous infusion J Antimicrob Chemother 2010 ; 65: 1073-1075

3152	髪題	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	髪題	Legrís ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilit� physique par �valuation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3254	髪題	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	髪題	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilit� physique de la naloxone avec d�autres m�dicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3475	髪題	Chen L.Y, Chen J, Waters V, Boodhan S. Incompatibility of ciprofloxacin and meropenem injections. Am J Health-Syst Pharm 2013 ;70:1966-1970.
3549	螳滄	Amikacine B Braun - R�sum� des caract�ristiques du produit. B Braun 2012
3595	螳滄	Aciclovir - Summary of Product Characteristics Hospira 2009
3674	螳滄	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3767	髪題	Legrís M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilit� par �valuation visuelle du thiopental injectable lors de son administration en Y avec des m�dicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	髪題	Boudi S, Roy H, Forest JM, Leclair G. Compatibilit� physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres m�dicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	網昂せ縹網シ	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	網昂せ縹網シ	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	網昂せ縹網シ	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
3837	髪題	Jaruratanasirikul S, Sriwiriyan S. Stability of meropenem in normal saline solution after storage at room temperature. South Asian J Trop Med Pub Health 2003 ; 34: 627-629.
3879	髪題	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3922	髪題	Wiesholzer, Winter A, Kussmann M, Zeitlinger M, Pichler P, Burgmann H, Reznicek G, Poeppl W. Compatibility of meropenem with different commercial dialysis solutions. Perit Dial Int 2016 doi:10.3747/pdi.2016.0001

3948	髪題	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P. Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	髪題	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilit� du citrate de caf�ine injectable avec plusieurs autres m�dicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	髪題	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3997	髪題	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	髪題	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4122	髪題	Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S. Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion. Hosp Pharm 2018 ;54,3:190-196
4145	髪題	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4147	髪題	Carlier M, Stove V, Verstraete A.G, De Waele J.J. Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiologica 2014 ;81,3:283-287
4180	髪題	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4290	髪題	Venugopalan V, Manigaba K, Borgert S.J, Cope J, Peloquin C.A, Klinker K.P. Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiology Insights 2018 ; 11, 1-6
4319	髪題	Lessard J-J, Caron E, Sch�rer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4326	髪題	Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Alban�se J, Vanelle P. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie 2019 ; 74: 357-362.
4380	螳滄	Posaconazole (Noxafil�) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	髪題	C���� K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilit� physique des m�dicaments administr�s en Y aux soins intensifs, en particulier la dexm�d�tomidine, le l�vosimendan et la k�tamine. Pharmactuel 2019 ;52,4:206-213
4403	髪題	De Souza Barbosa F, Capra Pezzi L, Tsao M, Manoela Dias Macedo S, Franco de Oliveira T, Schapoval EES, Mendez ASL. Stability in clinical use and stress testing of meropenem antibiotic by direct infusion ESI-Q-TOF: Quantitative method and identification of degradation products. J Pharm Biomed Anal 2020 ; 179: 112973.

4405	髪題	Ezquer-Garin C, Ferriols-Lisart R, Martinez-López LM, Sangrador-Pelluz C, Nicolás-Picó J, Alzás-Almí 7ana M. Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures Pharmazie 2020 ; 75: 172-176.
4434	髪題	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	髪題	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4465	髪題	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4470	髪題	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4528	髪題	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	髪題	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292-295
4572	髪題	Gostynska A, Piwowarczyk L, Nadolna M, Jelinska A, Dettlaff K, Ogrodowczyk M, Popielarz-Brzezinska M, Stawny M. Toward Safe Pharmacotherapy: The Interplay between Meropenem and Parenteral Nutrition Admixtures. Antibiotics 2021 ; 10: 715.
4592	髪題	Antibiotics 2021 ; 10: 715. The Role of Non-Enzymatic Degradation of Meropenem Antibiotics 2021 ; 10: 715.
4603	髪題	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	髪題	Loeuille G, Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4654	網帛せ縋シ	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeo lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	髪題	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'aminophylline injectable avec 102 autres médicaments lors d'administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

4801	髮題	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	髮題	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page 全harp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079 087.
4845	髮題	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4922	髮題	Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD. Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. J Allergy Clin Immunol Pract 2024 13, 2: 343-352.
5066	螳滄	Meropenem 500mg powder for solution for injection/ infusion - Summary of Product Characteristics Updated 21-Aug-2024. Bowmed Ibisqus Limited 2024



雲樊寫

	諡苓曙阮ヤ		豕イ蟆 脈
	蝠 刀蜷		貅カ蟬貞 縵ヨ螳牙ヨ壽 ア
	螳ケ蝎イ		蛻 ュ
	玃 コヲ		貂ウ蟒ヲ
	莖晉ヨ。		螳牙ヨ壽悄髭
	縵舌ウ縵エ縵キ縵湓△縵シ		遏帷峯縵呐k縵 縵ソ
	螻慕畑譚 鍵		縵ヤ縵ウ縵ケ
	豕イ蟆 畑豌エ		驕ヨ蜈
	譌・		？ 逆ケ險控↑縵
	譌る俣		▲ NaCl 0,9%
	縵-縵ヲ縵ウ縵シ縵ケ 包シ		▲ NaCl 0.9% + 縵輔お縵弱 縵ヲ 0.4%
	PVC 縵昂M蜴ウ蛹悶ン縵九N (PVC)		EXTRANEAL 縵ツヨ (Baxter)
	POF 縵昂M縵エ縵ヤ縵輔ウ縵ウ		蜈会シ城 蜈
	縵キ縵エ縵ウ縵ケ 縵昂M縵励O縵斐E縵ウ		蜈
	縵昂M縵、縵ス縵励E縵ウ縵イ縵ウ縵ケ縵医		？ 縵イ縵ウ縵ケ縵医 縵シ 郁ウ邏-荳肴
	？ 謬 ュ壹↑縵		貅キ蜷域函縵ヨ螳牙ヨ壽 ア
	貅カ蟬		蛹門粹逆ウ
	Δ ^o P1 1.5% glucose (Baxter)		Δ ^o P2 4.25% glucose (Baxter)
	Δ ^o P2 2.5% glucose (Baxter)		PP 縵昂M縵励O縵斐E縵ウ
	螳牙ヨ壽 ア縵ヲ蟆ア髻ソ縵呐k蝗 蟄		➡ 隠倅-
	螳牙ヨ壽 ア貂帛-		↑ 蠅怜刈
	蛻 ア」		莠呈鋤諤ア
	蛻ウ譌る到豌エ		髭櫟コ呈鋤
	荳咲音螳壹 髭櫟コ呈鋤諤ア		墓ヒ蠹
	蛹門ユヲ迄 ク紳ヨ牙ヨ壽 ア		1譌る俣蠕後 髻肴-エ
	縵エ縵		4譌る俣蠕後 潤イ縵ヨ蜈牙喧
	4譌る俣蠕後 髻肴-エ		15蛻 ヒ後 豐域ヨソ
	髭櫟ヲ悟哨迄)、奇シ郁p 関エ蜷ヲ縵		縵呐\$縵ヲ玃√j
	4譌る俣蠕後 縵イ縵械N縵ク縵ア縵ウ縵ヨ		髭櫟ヲ悟哨迄)、奇シ井コ悟 貅キ蜷育黄
	Physion 縵ツヨ (Baxter)		1譌る俣蠕後 潤イ縵ヨ蜈牙喧

RL	惹ウ驟ク縑エ縑ウ縑イ縑ォ		Dianヂャalツォ 1.5% glucose (Baxter)
	Dianヂャalツォ 2.5% glucose (Baxter)		Dianヂャalツォ 4.25% glucose (Baxter)
	潤イ螟画戔		15蛻 ㄗ貳√ j
	琬玲ウ。縑ョ逕滓		謐穂ク守ォ瑚キッ
	髻呵 ㄠ蜀		轡ケ貳エ髻呖ウィ
	螻慕畑譚 鍵		霎樊寫